Of the many treatments used in scleroderma (progressive systemic sclerosis), none has so far been shown to alter the fundamental course of the disease (see review Bywaters and Scott, 1965) .
Although corticosteroids may give symptomatic benefit in the early stages (Rodnan, Black, Bollet, and Bunim, 1956 ), prolonged therapy is unrewarding (Zion, Goldberg, and Suzman, 1955) . Several other promising treatments such as relaxin (Jefferis and Dixon, 1962) and epsilon-aminocaproic acid (Hall and Scott, 1966) have not stood the test of a controlled study.
Since their introduction in the late 1940s, dextrans have come to occupy an important place in clinical medicine. Low molecular weight dextran increases peripheral circulation by reducing both blood viscosity and intravascular red cell aggregation (Gelin and Zederfeldt, 1960) and an extensive literature has accumulated on its use in peripheral vascular disorders (Powley, 1964) .
Digital ischaemia is a prominent feature of scleroderma, yet scanty information is available on the use of low molecular weight dextran in this disease. Holti (1965) convincingly demonstrated that intermittent infusions temporarily improved digital ischaemic phenomena in ten out of twelve patients with scleroderma and noted that "these patients claimed to be remarkably better in themselves with an increased exercise tolerance and softening of their indurated facial skin". Using Holti's technique, Denis (1967) found a similar circulatory improvement in five of seven patients. In addition joint stiffness improved in some patients, dysphagia lessened in one, and facial telangiectasis in another. Kantor (1966) treated five scleroderma patients with single dextran infusions; in one the skin texture "improved about 50 per cent.", and in the remainder "a decided softening of the acral skin" was noted.
Scleroderma is not primarily a vascular disease. Although dextran may temporarily improve the digital circulation, the important question of whether the course of progressive systemic sclerosis itself is inttluenced needed to be resolved in a carefully controlled clinical evaluation.
Material and Methods
Six patients with scleroderma were selected for this study, the duration of disease ranging from early (6 months) to late (29 years), and the severity from mild and static to rapidly progressive (Table I, overleaf). All six showed clinical evidence of digital ischaemia including pulp pitting and atrophy ( Fig. 1) and painful digital ulceration. Intravenous infusions of low molecular weight dextran (10 per cent. W/V in normal saline) were given according to the method of Holti (1965) . Patients were admitted to hospital an average of four times at 3 to 5 week intervals to receive a continuous infusion of 2 1. dextran given over 48 hours on each occasion.
After a preliminary study in four patients, two of these and two others were admitted to a trial in which each patient was given a course of either dextran or normal saline, the treatment being allocated in a double-blind fashion. In patients who received both substances, at least 3 months elapsed between courses.
Assessment
The effects of treatment were assessed before and a week after the course of infusions by the following methods:
(1) Detailed symptomatic enquiry.
(2) Hands: Grip strengths, jeweller's ring sizes, palm printing, or serial plaster models (Fig. 4) according to the degree of deformity.
(3) Photographic recording of skin ulceration, telangiectasis, facial appearances, etc.
(4) Joints and contractures: Ranges of movement,
-assessment of pfain-and stiffness, serial joint radiographs.
(5) Digital bloodflow: Changes in finger tip temperature using radiometer measurement of radiant heat emission during standardized reflex body warming.
(6) Serial chest radiograph, electrocardiograph, blood examination, and other investigations where appropriate. (Portex, 23 Guage) inserted into small superficial veins and held in place by a plaster of paris shell. This method is recommendded for similar procedures.
The dextran itself was not universally well tolerated by patients. A hypersensitivity reaction in the form of fever and generalized rash developed in one woman with a history of allergy to other agents. In another, migrainous attacks, to which she was otherwise infrequently subject, accompanied two out of five infusions and transient generalized pruritis with a fine macular rash occurred once although the causal relationship was not established with certainty.
Discussion
Dextrans are the polysaccharides formed by Leuconostoc Mesenteroides cultured in a sucrosecontaining medium (Ricketts, 1961) . The British Pharmacopoeia contains three dextrans with average molecular weights 150,000 (Dextran 150 B.P.), 110,000 (Dextran 110 B.P.), and 40,000 (Dextran 40 B.P.).
The relative properties of dextrans are largely dependent on their molecular weight (Gronwall, 1957) . Low molecular weight dextran increases blood flow in the microcirculation by means of a disaggregating effect on human erythrocytes (Gelin and Ingelman, 1961 ), a reduction in whole blood viscosity at low flow rates in excess of the effect of haemodilution (Gregersen, Peric, Usami, Chien, Chang, and Sinclair, 1963) , and an increase in intravascular volume leading to increased venous return and cardiac output (Schenk, Delin, Domanig, Hahnloser, and Hoyt, 1964) . The duration of action depends mainly on the renal threshold for dextran which is around molecular weight 50,000.
In view of the established place of dextran in the treatment of peripheral vascular disorders, it is reasonable that this agent should be suggested for use in scleroderma in which a regular feature is digital ischaemia due to intimal thickening of the digital arteries and peripheral microthromboses. Previous reports (Holti, 1965; Denis, 1967) and our own experience confirm that peripheral tissue perfusion is enhanced in at least 50 per cent. of patients although the benefit is usually transient.
However, ischaemia accompanies but is not the cause of scleroderma and the improvement in circulation with dextran, although welcome, does not necessarily presage an improvement in the sclerodermatous involvement of tissues. Encouraging initial reports, such as that of Klein and Harris (1955) The use of saline control infusions has illustrated these aspects. One patient experienced the same subjective benefit with both saline and dextran. She felt better and was pleased with both treatments in spite of an obvious progression in her disease. Dysphagia first appeared during dextran infusions and subsided with saline. A modest improvement in one of the complaints of another patient, axillary contractures, coincided with a course of saline infusions. This may ordinarily have been ascribed to the treatment being evaluated.
Low molecular weight dextran is essentially a safe treatment, but acute renal failure (Morgan, Little, and Evans, 1966) Si bien pudiera ocurrir mejora temporal en la circulaci6n digital, el curso de la enfermedad misma parece inalterado. Este tratamiento podria, sin embargo, ser iitil en la terapia del fen6meno isquemico periferico que acompafia a la esclerodermia.
